News & Events
NGT3 VC announces its two latest investments: EIO Biomedical and Barcode Diagnostics
NGT3 – Press Release
NGT3 VC announces its two latest investments:
EIO Biomedical and Barcode Diagnostics
- EIO Biomedical preventing post-surgical adhesions
- Barcode Diagnostics provides oncologists with a powerful personalized treatment decision tool for optimal drug selection
- NGT3 VC and its two portfolio companies will participate at BIO 2017
Nazareth, Israel, 12.6. 2017:
NGT3 announces its two latest investments: EIO Biomedical, developing a unique solution to the huge unmet market need of surgical adhesion preventions, and Barcode Diagnostics, developing a proprietary solution for oncologists for personal cancer drug screening.
Zohar Gendler, NGT3 CEO & Managing Partner stated, “We are pleased to present at the San Diego BIO 2017 under the Israeli Authority for Innovation umbrella, presenting two new breakthrough technologies with solid intellectual property coverage, backed with great science and led by experienced management. These two companies have great potential to become real game changers".
Gary Jacobs from San Diego, NGT3 Chairman: "I have been investing in Israeli startups for over a decade, and I am especially proud of NGT3 which identifies innovative technologies and establishes early stage companies in the medical field. EIO Medical and Barcode Diagnostics are only two examples of NGT3's rich diversified portfolio of companies".
NGT3 is an early-stage VC, focused on life science technologies, holder of a franchise from the Israeli Government to operate a technology incubator (www.ngt3vc.com).
Surgical adhesions are one of the most pressing problems in general surgery today. Adhesions lead to a variety of post-operative complications and are a major unmet need.
Eio's proprietary novel product is fully biocompatible, biodegradable, and significantly reduces the occurrence and extent of post-surgical adhesion formation. Current estimates expects the US and European markets to reach over $10 Billion by 2020. http://www.ngt3vc.com/eio-biomedical/
Over 1.6M new cancer cases are diagnosed annually In the US alone. 30% of them do not receive the optimal treatment.
Barcode is developing a proprietary technology for personal cancer drug screening that will provide oncologists with a powerful personalized treatment decision tool for optimal drug selection.
Our solution includes:
- Screening of multiple drugs simultaneously
- Direct diagnostics of the treatment efficacy on the tumor within the patient body
- Sampling the drug efficiency on different cells types within the tumor
- A Fast (48-72 hours) and reliable screening method
Zohar Gendler, Managing Partner, CEO
email@example.com, +972 544308333